Multimodality (functional imaging)- adapted dose modification in head and neck cancer radiation therapy / (Record no. 178235)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 07373namaa22004571i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20260215100309.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 260207s2024 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99491 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 616.99491 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.19.06.Ph.D.2025.Ro.M |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Roa AbdulRahim Hassan Eltagy, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Multimodality (functional imaging)- adapted dose modification in head and neck cancer radiation therapy / |
| Statement of responsibility, etc. | by Roa AbdulRahim Hassan Eltagy ; Supervision Prof. Tarek Hamed Shouman, Dr. May Gamal Ashour, Prof. Ayda Aly Youssef, Dr. Esraa Ahmed Morsi El-Kholy. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | التصوير المتعدد الأساليب لتكييف الجرعة المعدلة فى علاج سرطان الرأس والرقبة بالأشعاع |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 105 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 82 -103. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Background: <br/>Head and neck squamous cell carcinoma (HNSCC) remains a significant <br/>global health burden, with high rates of locoregional recurrence and treatment-<br/>related morbidity. Advances in functional imaging modalities, such as 18F-<br/>fludeoxyglucose (FDG) PET/CT and diffusion-weighted (DWI) Magnetic <br/>Resonance Imaging (MRI), have enabled better risk stratification and early response <br/>assessment. These tools present new opportunities for personalized treatment <br/>through adaptive radiotherapy and stereotactic body radiotherapy (SBRT)-based <br/>dose escalation. <br/><br/>Objectives: <br/>This prospective phase II study aimed to evaluate the feasibility, safety, <br/>and clinical utility of response-adapted SBRT dose escalation in HNSCC patients <br/>based on interim functional imaging. Specifically, it assessed whether early <br/>metabolic and diffusion changes can predict outcomes and guide individualized <br/>treatment intensification. <br/><br/>Patients and Methods: <br/>Seventy-two patients with histologically confirmed HNSCC were enrolled <br/>between 2019 and 2022. Baseline and interim imaging using FDG PET/CT and DWI <br/>MRI were performed during radiotherapy. Patients were stratified into good and <br/>poor responders based on metabolic response (≥50% Standardized Uptake Value <br/>(SUV) max reduction) and Apparent Diffusion Coefficient (ADC) changes. Poor <br/>responders received additional SBRT boosts to primary tumor sites. Clinical <br/><br/><br/> 10 <br/><br/>outcomes, toxicity profiles, and survival data were analyzed with respect to interim <br/>imaging responses. <br/><br/>Results: <br/><br/>Among 72 evaluable patients, 62.5% demonstrated a good PET/CT <br/>response. A significant reduction in SUVmax and an increase in ADC values were <br/>observed mid-treatment (p < 0.001). Good responders achieved higher rates of <br/>complete response (96% vs. 66.7%, p < 0.001) and superior 2-year locoregional <br/>control (75% vs. 59%, p = 0.041) compared to poor responders. SBRT boost was <br/>well tolerated, with no grade 5 toxicities and a low incidence of grade ≥3 late <br/>toxicities. However, disease-free and overall survival did not significantly differ <br/>between response groups. <br/><br/>Conclusion: <br/>Interim PET/CT and DWI MRI are reliable predictors of treatment <br/>response in HNSCC and can safely guide SBRT-based dose escalation. While this <br/>strategy improved locoregional control in good responders, outcomes in poor <br/>responders remain suboptimal, suggesting a need for further therapeutic innovation. <br/>This study supports the feasibility of functional imaging-guided personalized <br/>radiotherapy and lays the groundwork for future adaptive treatment protocols in <br/>HNSCC. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | الخلفية العلمية و الهدف من الرساله:<br/>لا يزال سرطان الخلايا الحرشفية في الرأس والعنق (HNSCC) يشكّل عبئًا صحيًا عالميًا كبيرًا، نظرًا لارتفاع معدلات التكرار الموضعي والإقليمي والمضاعفات المرتبطة بالعلاج. لقد مكّنت التطورات في تقنيات التصوير الوظيفي مثل التصوير المقطعي بالإصدار البوزيتروني باستخدام ^18F-FDG والتصوير بالرنين المغناطيسي الموزون بالانتشار (DWI) من تحسين تصنيف المخاطر وتقييم الاستجابة المبكرة. وتوفر هذه الأدوات فرصًا جديدة للعلاج الشخصي من خلال العلاج الإشعاعي التكيفي وتصعيد الجرعة باستخدام العلاج الإشعاعي التجسيمي للجسم (SBRT).<br/>طرق البحث :<br/>تم تسجيل اثنين وسبعين مريضًا تم تأكيد إصابتهم بـ HNSCC نسيجيًا بين عامي 2019 و2022. تم إجراء التصوير الأساسي والوسيط باستخدام FDG PET/CT وDWI MRI خلال العلاج الإشعاعي. تم تصنيف المرضى إلى مستجيبين جيدين وضعفاء بناءً على الاستجابة الاستقلابية (انخفاض ≥50% في SUVmax) وتغيرات قيمة ADC. تلقى المستجيبون الضعفاء جرعات إضافية من SBRT إلى مواقع الأورام الأولية. تم تحليل النتائج السريرية، وملفات السمية، وبيانات البقاء على قيد الحياة بالنسبة للاستجابة في التصوير الوسيط.<br/>النتائج:<br/>من بين 72 مريضًا قابلين للتقييم، أظهر 62.5% استجابة جيدة في PET/CT. لوحظ انخفاض كبير في SUVmax وزيادة في قيم ADC في منتصف العلاج (p < 0.001). حقق المستجيبون الجيدون معدلات استجابة كاملة أعلى (96% مقابل 66.7%، p < 0.001) وتحكمًا موضعيًا/إقليميًا أفضل خلال عامين (75% مقابل 59%، p = 0.041) مقارنة بالمستجيبين الضعفاء. تم تحمل جرعة SBRT المعززة بشكل جيد، دون حدوث سمّية من الدرجة الخامسة، وبمعدل منخفض من السمية المتأخرة من الدرجة الثالثة أو أعلى. ومع ذلك، لم يكن هناك اختلاف كبير في البقاء بدون |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Head and Neck Cancer |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | سرطان الرأس والرقبة |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Radiotherapy |
| -- | Multimodality Imaging |
| -- | Head and Neck Cancer |
| -- | علاج اشعاعي |
| -- | سرطان الرأس والرقبة |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tarek Hamed Shouman |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | May Gamal Ashour |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ayda Aly Youssef |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Esraa Ahmed Morsi El-Kholy |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2024 |
| Supervisory body | Tarek Hamed Shouman |
| -- | May Gamal Ashour |
| -- | Ayda Aly Youssef |
| -- | Esraa Ahmed Morsi El-Kholy |
| Universities | Cairo University |
| Faculties | National Cancer Institute |
| Department | Department of Radiation Oncology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 07.02.2026 | 93303 | Cai01.19.06.Ph.D.2024.Ro.M | 01010110093303000 | 07.02.2026 | 07.02.2026 | Thesis |